FES is applied to lower extremities for improving functional walking in stroke patients;  for the correction of foot drop. They have benefited patients by improving gait speed, muscle strength and other functions.Treatment for some can be as easy as an underside "L" shaped foot-up ankle support (ankle-foot orthoses). Another method uses a cuff placed around the patients ankle, and a topside spring and hook installed under the shoelaces. The hook connects to the ankle cuff and lifts the shoe up when the patient walks. Both these techniques show significant improvement on usage. Identification of a suspect in a murder case
In December 2021, police in Toronto, Canada said they were looking for a person with a distinctive gait as a suspect in the murder of Barry Sherman and Honey Sherman. Medical professionals  quoted by the Toronto Star said that the distinctive gait could  be caused by foot drop. See also
Yoga foot drop
Toe walking
Polymyositis
inclusion body myositis

References
Further reading
Agency for Healthcare Research and Quality (2011). Healthcare Cost and Utilization Project. Balali-Mood, Mahdi (January 2008). "Neurotoxic disorders of organophosphorus compounds and their managements". Arch Iran Med. 11(1):65–89. PMID 18154426. Jokanovic, Milan, Melita Kosanovic, Dejan Brkic, and Predrag Vukomanovic (2011). "Organophosphate Induced Delayed Polyneuropathy in Man: An Overview". Clinical Neurology and Neurosurgery 113.1: 7–10. PMID 20880629. doi:10.1016/j.clineuro.2010.08.015. Mayo Clinic. "Foot Drop". Pritchett, James W., MD (June 21, 2018). "Foot Drop". Vinod K Panchbhavi, MD, FACS (ed.). Saladin, Kenneth (2015). Anatomy & Physiology: A Unity of Form & Function. 7th ed. New York: McGraw-Hill Education. Print.
A small assessment of sustained release of 0.4 mg belladonna alkaloids and ~60 mg phenobarbital (1 grain) was performed in patients with functional GI disorders (i.e., gastric hyperacidity, dyspepsia, pyrosis, gas pains and epigastric distress. Overall, 23 of 25 patients reported complete or significant relief of symptoms. Hock also examined the effect of 0.25 mg belladonna alkaloids and 50 mg phenobarbital sustained release formulation in 82 clinical practice patients with various gastrointestinal disturbances including “functional distress” over 27 months. Of the 82 total patients, 33 patients reported a 50-75% and 20 reported a 75-100% improvement. There were specific reports of improvements in pain and bowel habits in over half of the patients. One of the earliest randomized double-blind clinical trials of belladonna alkaloids + phenobarbital was in 1959 by Lichstein et al. The study involved 75 patients with unstable bowel (whose symptoms are typical or similar to a current diagnosis of IBS) to investigate the combination therapy of an anticholinergic with the addition of phenobarbital against placebo over 15 months. Of these patients, 20 were treated with placebo, 43 were treated with 50 mg phenobarbital in combination with 0.25 mg Belladonna alkaloids, and 12 received both therapies (patients who lacked a response were switched therapy). Of those receiving the belladonna alkaloids / phenobarbital only, 75.6% reported a mean improvement (2+ or better) in all categories. Among the placebo patients only, only 29.8% reported mean improvement in symptoms.